Cited by 637Psychedelics and Drug StudiesParanormal Experiences and BeliefsReligion, Spirituality, and Psychology

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Open access

Barrett, Frederick S, Johnson, Matthew W, Griffiths, Roland R·2015·Journal of Psychopharmacology

DOI 10.1177/0269881115609019PMC PMC5203697

Open this paper in CoChat — free account

Abstract

The 30-item revised Mystical Experience Questionnaire (MEQ30) was previously developed within an online survey of mystical-type experiences occasioned by psilocybin-containing mushrooms. The rated experiences occurred on average eight years before completion of the questionnaire. The current paper validates the MEQ30 using data from experimental studies with controlled doses of psilocybin. Data were pooled and analyzed from five laboratory experiments in which participants ( n=184) received a moderate to high oral dose of psilocybin (at least 20 mg/70 kg). Results of confirmatory factor analysis demonstrate the reliability and internal validity of the MEQ30. Structural equation models demonstrate the external and convergent validity of the MEQ30 by showing that latent variable scores on the MEQ30 positively predict persisting change in attitudes, behavior, and well-being attributed to experiences with psilocybin while controlling for the contribution of the participant-rated intensity of drug effects. These findings support the use of the MEQ30 as an efficient measure of individual mystical experiences. A method to score a “complete mystical experience” that was used in previous versions of the mystical experience questionnaire is validated in the MEQ30, and a stand-alone version of the MEQ30 is provided for use in future research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1177/0269881115609019

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives
Hu, L., & Bentler, P. M. (1999) · Structural Equation Modeling A Multidisciplinary Journal · doi:10.1080/10705519909540118 · Cited by 108,788
lavaan : An R Package for Structural Equation Modeling
Rosseel, Y. (2012) · Journal of Statistical Software · doi:10.18637/jss.v048.i02 · Cited by 27,955
Alternative Ways of Assessing Model Fit
Browne, M. W., & Cudeck, R. (1992) · Sociological Methods & Research · doi:10.1177/0049124192021002005 · Cited by 27,200
Confirmatory factor analysis for applied research
Brown, T. A. (2007) · Choice Reviews Online · doi:10.5860/choice.44-2769 · Cited by 15,621
Testing Structural Equation Models.
Mueller, C. W., Bollen, K. A., & Long, J. S. (1994) · Contemporary Sociology A Journal of Reviews · doi:10.2307/2074955 · Cited by 14,211
EQS : structural equations program manual
Bentler, P. M. (1989) · Medical Entomology and Zoology · Cited by 9,669
Detection Theory: A User's Guide
Macmillan, N. A., & Creelman, C. D. (1991) · Cited by 5,415
A scaled difference chi-square test statistic for moment structure analysis
Satorra, A., & Bentler, P. M. (2001) · Psychometrika · doi:10.1007/bf02296192 · Cited by 5,282
The varieties of religious experience: A study in human nature.
James, W. (1902) · doi:10.1037/10004-000 · Cited by 5,204

Show all 34 references

Research works printed but not linked: 3

Pahnke WN, 1963, Drugs and Mysticism: An Analysis of the Relationship Between Psychedelic Drugs and the Mystical Consciousness
Pahnke WN, 1967, LSD Man & Society, 60
Richards WA, 1975, Counseling, Peak Experiences and the Human Encounter with Death: An Empirical Study of the Efficacy of DPT-Assitance Counseling in Enhancing Quality of Life of Persons with Terminal Cancer and Their Closest Family Members

Sorted by citations

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
“Thirty items on the SOCQ comprise the Mystical Experience Questionnaire (MEQ30), which was shown sensitive to mystical-type subjective effects of psilocybin in laboratory studies as well as survey studies of recreational use of psilocybin mushrooms (Barrett et al., 2015; MacLean et al., 2012).”
BackgroundSelf-citation
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Self-citation
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
The subjective effects of psychedelics are necessary for their enduring therapeutic effects
Yaden, D. B., & Griffiths, R. R. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00194 · Cited by 541
Self-citation
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662634 · Cited by 596
Self-citation
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117731279 · Cited by 520
Self-citation
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Self-citation
Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI).
Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00269 · Cited by 470
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up.
Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073759 · Cited by 425
Self-citation
Predicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417
Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety
Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375
Self-citation
Psychedelics as Medicines: An Emerging New Paradigm
Nichols, D. E., Johnson, M., & Nichols, C. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.557 · Cited by 397
Self-citation
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116678781 · Cited by 366
“, 2016) and mystical experience (Barrett et al., 2015) are positively associated with well-being, it is not completely clear that the items of the ‘death’ subscale of the CEQ (“Profound experience of your own death” and “Feel as if dead or dying”) are collinear with either mystical experience or ego dissolution.”
Self-citation
Psychedelics, mystical experience, and therapeutic efficacy: a systematic review
Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.917199 · Cited by 306
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119845793 · Cited by 225
Self-citation
Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates
Barrett, F. S., & Griffiths, R. R. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_474 · Cited by 273
Self-citation
Psilocybin desynchronizes the human brain
Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., Reneau, T. R., Metcalf, N. V., Chacko, R. V., Gratton, C., et al. (2024) · Nature · doi:10.1038/s41586-024-07624-5 · Cited by 308
Psychedelics and connectedness
Carhart-Harris, R. L., Erritzøe, D., Haijen, E. C. H. M., Kaelen, M., & Watts, R. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4701-y · Cited by 278
Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247
Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
Holze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00883-6 · Cited by 245
Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT
Griffiths, R. R., Hurwitz, E. S., Davis, A. K., Johnson, M. W., & Jesse, R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214377 · Cited by 268
Self-citation
Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression
Murphy, R., Kettner, H., Zeifman, R., Giribaldi, B., Kartner, L., Martell, J., Read, T., Murphy-Beiner, A., Baker-Jones, M., Nutt, D., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.788155 · Cited by 250
Long-lasting subjective effects of LSD in normal subjects.
Schmid, Y., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4733-3 · Cited by 232
Psychedelics, personality and political perspectives.
Nour, M. M., Evans, L., & Carhart-Harris, R. L. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1312643 · Cited by 226
Psychedelics alter metaphysical beliefs
Timmermann, C., Kettner, H., Letheby, C., Roseman, L., Rosas, F. E., & Carhart-Harris, R. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-01209-2 · Cited by 243
Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
Holze, F., Ley, L., Müller, F., Becker, A. M., Straumann, I., Vizeli, P., Kuehne, S. S., Roder, M. A., Duthaler, U., Kolaczynska, K. E., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01297-2 · Cited by 226
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221
DMT Models the Near-Death Experience
Timmermann, C., Roseman, L., Williams, L., Erritzøe, D., Martial, C., Cassol, H., Laureys, S., Nutt, D., & Carhart-Harris, R. L. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01424 · Cited by 243
Human brain effects of DMT assessed via EEG-fMRI
Timmermann, C., Roseman, L., Haridas, S., Rosas, F. E., Luan, L., Kettner, H., Martell, J., Erritzøe, D., Tagliazucchi, E., Pallavicini, C., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218949120 · Cited by 232
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Liechti, M. E., Dolder, P. C., & Schmid, Y. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4453-0 · Cited by 198
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
Garcia‐Romeu, A., & Richards, W. A. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1486289 · Cited by 210
Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention
Barrett, F. S., Krimmel, S. R., Griffiths, R. R., Seminowicz, D. A., & Mathur, B. N. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.116980 · Cited by 199
Self-citation
A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding
Madsen, M. K., Fisher, P. M., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., Páleníček, T., Kuchař, M., Svarer, C., Ozenne, B., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.02.001 · Cited by 183
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects
Becker, A. M., Holze, F., Grandinetti, T., Klaiber, A., Toedtli, V. E., Kolaczynska, K. E., Duthaler, U., Varghese, N., Eckert, A., Grünblatt, E., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2487 · Cited by 184
Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness
Kettner, H., Rosas, F. E., Timmermann, C., Kärtner, L., Carhart-Harris, R. L., & Roseman, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623985 · Cited by 221
Unifying Theories of Psychedelic Drug Effects
Swanson, L. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00172 · Cited by 194
Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy
Hendricks, P. S. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1474185 · Cited by 188
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
Fuentes, J. J., Fonseca, F., Elices, M., Farré, M., & Torrens, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00943 · Cited by 177
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD
Davis, A. K., Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120967878 · Cited by 169
Self-citation
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Sloshower, J., Skosnik, P. D., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D’Souza, D. C. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231154852 · Cited by 165
Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey
Garcia‐Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., & Johnson, M. W. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00955 · Cited by 171
Self-citation
Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience
Madsen, M. K., Stenbæk, D. S., Arvidsson, A., Armand, S., Marstrand-Joergensen, M. R., Johansen, S. S., Línnet, K., Ozenne, B., Knudsen, G. M., & Fisher, P. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.06.001 · Cited by 155
Psychedelic harm reduction and integration: A transtheoretical model for clinical practice
Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.645246 · Cited by 147
Tripping on nothing: placebo psychedelics and contextual factors
Olson, J. A., Suissa-Rocheleau, L., Lifshitz, M., Raz, A., & Veissière, S. P. L. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05464-5 · Cited by 155
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety
Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1545024 · Cited by 142
Self-citation
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience
Peill, J. M., Trinci, K. E., Kettner, H., Mertens, L. J., Roseman, L., Timmermann, C., Rosas, F. E., Lyons, T., & Carhart-Harris, R. L. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211066709 · Cited by 141
Mystical and other alterations in sense of self: an expanded framework for studying nonordinary experiences.
Taves, A. (2020) · Perspectives on Psychological Science · doi:10.1177/1745691619895047 · Cited by 140
Future directions in meditation research: Recommendations for expanding the field of contemplative science
Vieten, C., Wahbeh, H., Cahn, B. R., MacLean, K., Estrada, M., Mills, P., Murphy, M., Shapiro, S., Radin, D., Josipovic, Z., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205740 · Cited by 124
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences
Carbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4769-4 · Cited by 133
Self-citation
Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants
Ley, L., Holze, F., Arikci, D., Becker, A. M., Straumann, I., Klaiber, A., Coviello, F., Dierbach, S., Thomann, J., Duthaler, U., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01607-2 · Cited by 130
The Nondual Awareness Dimensional Assessment (NADA): New tools to assess nondual traits and states of consciousness occurring within and beyond the context of meditation
Hanley, A. W., Nakamura, Y., & Garland, E. L. (2018) · Psychological Assessment · doi:10.1037/pas0000615 · Cited by 130
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use
Johnson, M. W., Garcia‐Romeu, A., Johnson, P. S., & Griffiths, R. R. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116684335 · Cited by 140
Self-citation
Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder
Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H., Amegadzie, S. S., Malone, T. C., Owens, L. T., Ross, S., & Mennenga, S. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00100 · Cited by 128
Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes
Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00018 · Cited by 124
The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions
Nielson, E. M., May, D. G., Forcehimes, A. A., & Bogenschutz, M. P. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00132 · Cited by 120
The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)
Reckweg, J. T., Uthaug, M. V., Szabó, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15587 · Cited by 126
Classic Psychedelic Drugs: Update on Biological Mechanisms
Vollenweider, F. X., & Smallridge, J. W. (2022) · Pharmacopsychiatry · doi:10.1055/a-1721-2914 · Cited by 119
The Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary Psychology
Winkelman, M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00539 · Cited by 116
Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses
McCulloch, D. E.-W., Knudsen, G. M., Barrett, F. S., Doss, M. K., Carhart-Harris, R. L., Rosas, F. E., Deco, G., Kringelbach, M. L., Preller, K. H., Ramaekers, J. G., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104689 · Cited by 110
Self-citation
Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants
Becker, A., Klaiber, A., Holze, F., Istampoulouoglou, I., Duthaler, U., Varghese, N., Eckert, A., & Liechti, M. E. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac075 · Cited by 111
Association between mystical-type experiences under psychedelics and improvements in well-being or mental health – A comprehensive review of the evidence
Kangaslampi, S. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00243 · Cited by 111
People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences
Williams, M. T., Davis, A. K., Xin, Y., Sepeda, N. D., Grigas, P. C., Sinnott, S., & Haeny, A. M. (2021) · Drugs: Education, Prevention and Policy · doi:10.1080/09687637.2020.1854688 · Cited by 101
Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report
McCulloch, D. E.-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841648 · Cited by 119
Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches
Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121991822 · Cited by 96
Self-citation
A Meta-Analysis of Religion/Spirituality and Life Satisfaction
Yaden, D. B., Batz-Barbarich, C. L., Ng, V., Vaziri, H., Gladstone, J. N., Pawelski, J. O., & Tay, L. (2022) · Journal of Happiness Studies · doi:10.1007/s10902-022-00558-7 · Cited by 127
Set and setting: a randomized study of different musical genres in supporting psychedelic therapy
Strickland, J. C., Garcia-Romeu, A., & Johnson, M. W. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00187 · Cited by 97
Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments
Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94
Dose–response relationships of psilocybin-induced subjective experiences in humans
Hirschfeld, T., & Schmidt, T. T. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121992676 · Cited by 97
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
Nayak, S. M., Jackson, H., Sepeda, N. D., Mathai, D. S., So, S., Yaffe, A., Zaki, H., Brasher, T. J., Lowe, M. X., Jolly, D. R. P., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1199642 · Cited by 97
Self-citation
Belief changes associated with psychedelic use
Nayak, S. M., Singh, M., Yaden, D. B., & Griffiths, R. R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221131989 · Cited by 96
Self-citation
Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants
Vogt, S. B., Ley, L., Erne, L., Straumann, I., Becker, A. M., Klaiber, A., Holze, F., Vandersmissen, A., Mueller, L., Duthaler, U., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02477-4 · Cited by 89
Psychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82
“In healthy individuals, increased Openness is a key long-term effect of psychedelics; and interestingly, psilocybin studies in healthy individuals show that neocortex 5-HT 2A R binding as measured with PET is negatively associated with the peak-pla-teau duration of the experience and with the Mystical Experience Quest…”
Influential
A narrative synthesis of research with 5-MeO-DMT
Ermakova, A. O., Dunbar, F., Rucker, J., & Johnson, M. W. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211050543 · Cited by 94
Self-citation
High dose psilocybin is associated with positive subjective effects in healthy volunteers
Nicholas, C. R. N., Henriquez, K. M., Gassman, M., Cooper, K. M., Muller, D., Hetzel, S., Brown, R., Cozzi, N. V., Thomas, C., & Hutson, P. R. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780713 · Cited by 87
Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals
McCulloch, D. E.-W., Madsen, M. K., Stenbæk, D. S., Kristiansen, S., Ozenne, B., Jensen, P. S., Knudsen, G. M., & Fisher, P. M. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211026454 · Cited by 83
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice
Payne, J. E., Chambers, R., & Liknaitzky, P. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00034 · Cited by 78
Evoking the ineffable: The phenomenology of extreme sports.
Brymer, E., & Schweitzer, R. (2017) · Psychology of Consciousness Theory Research and Practice · doi:10.1037/cns0000111 · Cited by 82
Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study
Barsuglia, J. P., Davis, A. K., Palmer, R. L., Lancelotta, R., Windham-Herman, A.-M., Peterson, K., Polanco, M., Grant, R., & Griffiths, R. R. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.02459 · Cited by 90
Self-citation
Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans
Stenbæk, D. S., Madsen, M. K., Ozenne, B., Kristiansen, S., Burmester, D., Erritzøe, D., Knudsen, G. M., & Fisher, P. M. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120959609 · Cited by 83
Acute subjective effects in LSD- and MDMA-assisted psychotherapy
Schmid, Y., Gasser, P., Oehen, P., & Liechti, M. E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959604 · Cited by 85
Replication and extension of a model predicting response to psilocybin
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. M., & Elliott, M. S. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05279-z · Cited by 83
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder
Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300501 · Cited by 82
Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics
Moreton, S. G., Szalla, L., Menzies, R. E., & Arena, A. F. A. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05391-0 · Cited by 85
Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings
Pallavicini, C., Cavanna, F., Zamberlán, F., de la Fuente, L. A., Ilksoy, Y. A., Perl, Y. S., Arias, M., Romero, C., Carhart-Harris, R. L., Timmermann, C., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120981384 · Cited by 90
The Near-Death Experience Content (NDE-C) scale: Development and psychometric validation
Martial, C., Simon, J., Puttaert, N., Gosseries, O., Charland‐Verville, V., Nyssen, A., Greyson, B., Laureys, S., & Cassol, H. (2020) · Consciousness and Cognition · doi:10.1016/j.concog.2020.103049 · Cited by 77
A Single Belief-Changing Psychedelic Experience Is Associated With Increased Attribution of Consciousness to Living and Non-living Entities
Nayak, S. M., & Griffiths, R. R. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.852248 · Cited by 74
Self-citation
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Nygart, V. A., Pommerencke, L. M., Haijen, E. C. H. M., Kettner, H., Kaelen, M., Mortensen, E. L., Nutt, D. J., Carhart-Harris, R. L., & Erritzøe, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221101061 · Cited by 79
A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties
Sumner, R. L., Chacko, E., McMillan, R. L., Spriggs, M. J., Anderson, C., Chen, J., French, A., Jung, S., Rajan, A., Malpas, G. A., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121998321 · Cited by 77
Restructuring insight: An integrative review of insight in problem-solving, meditation, psychotherapy, delusions and psychedelics
Tulver, K., Kaup, K., Laukkonen, R., & Aru, J. (2023) · Consciousness and Cognition · doi:10.1016/j.concog.2023.103494 · Cited by 86
Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis
Li, N.-X., Hu, Y.-R., Chen, W.-N., & Zhang, B. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.09.041 · Cited by 72
HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer
Lewis, B. R., Garland, E. L., Byrne, K., Durns, T. A., Hendrick, J., Beck, A. C., & Thielking, P. D. (2023) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2023.06.006 · Cited by 70
An Integrated theory of false insights and beliefs under psychedelics
McGovern, H. T., Grimmer, H. J., Doss, M. K., Hutchinson, B. T., Timmermann, C., Lyon, A., Corlett, P. R., & Laukkonen, R. (2024) · Communications Psychology · doi:10.1038/s44271-024-00120-6 · Cited by 79
Psychedelics and psychotherapy
Nayak, S., & Johnson, M. W. (2021) · Pharmacopsychiatry · doi:10.1055/a-1312-7297 · Cited by 71
The Altered States Database: Psychometric Data of Altered States of Consciousness
Schmidt, T. T., & Berkemeyer, H. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01028 · Cited by 72
Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color
Davis, A. K., Xin, Y., Sepeda, N. D., Garcia-Romeu, A., & Williams, M. T. (2021) · Chronic Stress · doi:10.1177/24705470211035607 · Cited by 67
Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying
Sweeney, M. M., Nayak, S. M., Hurwitz, E. S., Mitchell, L. N., Swift, T. C., & Griffiths, R. R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271926 · Cited by 70
Self-citation
Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience
Stauffer, C. S., Anderson, B. T., Ortigo, K. M., & Woolley, J. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00169 · Cited by 65

Authors: Barrett, F. S., Johnson, M. W., & Griffiths, R. R.
Affiliations: Johns Hopkins University (US)
Corresponding author: Barrett, Frederick S
ORCID: Barrett, Frederick S
Johnson, Matthew W
Griffiths, Roland R
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2015-10-06
Volume: 29
Issue: 11
Pages: 1182-1190
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881115609019
PMC: PMC5203697
OpenAlex: W2340085151
Cited by: 637
References: 34
Citations by year: 2026: 91 · 2025: 110 · 2024: 123 · 2023: 78 · 2022: 78 · 2021: 53 · 2020: 38 · 2019: 12 · 2018: 20 · 2017: 21 · 2016: 12
FWCI: 21.94
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Drug Abuse (R01DA003889, T32DA007209, R01DA03889)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
Social Sciences › Health › Religion, Spirituality, and Psychology
Keywords: psilocybin, mystical experience, psychedelic drug effects, questionnaire validation, factor structure, convergent validity, attitude change, well-being
MeSH terms: Administration, Oral, Hallucinogens, Humans, Mysticism, Psilocybin, Surveys and Questionnaires

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks